Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Holding ATRC?
Track your performance easily
ATRC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.94 - $39.05
Previous Close$30.05
Volume768.30K
Average Volume (3M)514.46K
Market Cap
$1.47B
Enterprise Value$1.40B
Total Cash (Recent Filing)$130.34M
Total Debt (Recent Filing)$61.87M
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Feb 25, 2025EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding48,753,251
10 Day Avg. Volume488,099
30 Day Avg. Volume514,457
Standard Deviation0.13
R-Squared0.34
Alpha-0.00625
Financial Highlights & Ratios
Price to Book (P/B)3.22
Price to Sales (P/S)3.27
Price to Cash Flow (P/CF)18.30
P/FCF Ratio22.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.12
Enterprise Value/Gross Profit4.65
Enterprise Value/Ebitda-89.81
Forecast
1Y Price Target
$45.75Price Target Upside48.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Atricure News
PremiumCompany Announcements
AtriCure Reports Strong Growth in Q3 2024 Earnings
Bulls Say, Bears Say
Bulls Say
Partnerships And InnovationATRC entered into an exclusive license agreement to add PFA to their portfolio, suggesting potential for future growth.
Product ExpansionThe expansion of Encompass OUS for a full year alongside full years of cryoSPHERE+/MAX, AtriClip Flex Mini with its Chinese launch and CE mark label expansion gives ATRC a very nice set up for sustained momentum.
Revenue GrowthATRC reported Q3/24 revenue of $115.9M, which was above consensus expectations.
Bears Say
Financial GuidanceThe company lowered full-year 2024 guidance by ~$4 mln due to the relative softness within its MIS Ablation and MIS Appendage Management segments.
Growth ConcernsMinimally Invasive Ablation growth slowed due to pressure from PFA procedure volume.
Market DynamicsThe Minimally Invasive division came in just below consensus as market dynamics around the introduction of PFA continued.
---
Ownership Overview
3.17% Insiders
38.62% Mutual Funds
33.85% Other Institutional Investors
8.28% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ATRC FAQ
What was Atricure’s price range in the past 12 months?
Atricure lowest stock price was $18.94 and its highest was $39.05 in the past 12 months.
What is Atricure’s market cap?
Currently, no data Available
When is Atricure’s upcoming earnings report date?
Atricure’s upcoming earnings report date is Feb 25, 2025 which is in 66 days.
How were Atricure’s earnings last quarter?
Atricure released its earnings results on Oct 29, 2024. The company reported -$0.17 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.025.
Is Atricure overvalued?
According to Wall Street analysts Atricure’s price is currently Undervalued.
Does Atricure pay dividends?
Atricure does not currently pay dividends.
What is Atricure’s EPS estimate?
Atricure’s EPS estimate is -$0.21.
How many shares outstanding does Atricure have?
Atricure has 48,753,250 shares outstanding.
What happened to Atricure’s price movement after its last earnings report?
Atricure reported an EPS of -$0.17 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went up 18.349%.
Which hedge fund is a major shareholder of Atricure?
Among the largest hedge funds holding Atricure’s share is Royce & Associates LLC. It holds Atricure’s shares valued at 2M.
---
Atricure Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.75 (48.93% Upside)
$45.75 (48.93% Upside)
Blogger Sentiment
Bullish
ATRC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 28.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-16.22%
12-Months-Change
Fundamentals
Return on Equity
-8.39%
Trailing 12-Months
Asset Growth
2.46%
Trailing 12-Months
Company Description
Atricure
AtriCure, Inc. engages development, manufacture and sale of devices designed primarily for the surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio Frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, Other International, and Total International. The company was founded by Michael D. Hooven on October 31, 2000 and is headquartered in West Chester, OH.
---
ATRC Company Deck
---
ATRC Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance for AtriCure with significant revenue growth and positive cash flow. However, there are challenges in maintaining gross margins and increasing operating expenses. While the company is seeing pressure in certain areas due to market dynamics, the overall outlook remains positive with continued investments in innovation and market expansion.Read More>---
ATRC Stock 12 Month Forecast
Average Price Target
$45.75
▲(48.93% Upside)
Technical Analysis
Best Analysts Covering ATRC
1 Year
1 Year Success Rate
19/22 ratings generated profit
1 Year Average Return
+41.94%
reiterated a buy rating 2 months ago
Copying Suraj Kalia's trades and holding each position for 1 Year would result in 86.36% of your transactions generating a profit, with an average return of +41.94% per trade.
---